

Snap | 26 March 2024

# Singapore's industrial production sees surprise gain in February

Industrial production rose 3.8% YoY, driven by strong production of pharmaceuticals and petrochemicals



Production in biomedical, chemical and aerospace transport helped drive last month's upside surprise

3.8%

YoY growth for industrial production

Higher than expected

### February industrial production up 3.8%


Singapore's industrial production rose more than expected, gaining 3.8%year-on-year compared to a median forecast of 0.5% YoY. From the previous month, industrial production jumped 14.2%, much stronger than expectations for a modest 2.1% rise.

Production in biomedical, chemical and aerospace transport helped provide the upside surprise and were up 27.4% YoY, 11.2% YoY and 37.3% YoY respectively.

Snap | 26 March 2024 1

Meanwhile, electronics rose at a more measured pace, up 2.6% YoY, with the drop in computer peripherals partially offset by a strong showing for consumer electronics and semiconductors. February's 3.8% gain was a notable pickup from the 0.6%YoY increase reported in January.

### Singapore industrial production up even after surprise dip for NODX



Source: Singapore Department of Statistics

## Upside surprise for IP welcome but too soon to indicate recovery

The better-than-expected gain for industrial production bodes well for the first quarter GDP report alongside a likely jump in retail sales in March. We had initially expected industrial production to report a modest increase given the disappointing non-oil domestic exports report for the same month.

It may still be too soon, however, to gauge whether the February surprise represents a strong turnaround for the sector and we may need to see a sustained pickup in external demand to help drive a similar pace of growth for industrial production in 2024.

### **Author**

#### Nicholas Mapa

Senior Economist, Philippines nicholas.antonio.mapa@asia.ing.com

#### Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies). The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

Snap | 26 March 2024

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit http://www.ing.com.

Snap | 26 March 2024 3